시장보고서

상품코드

1756412

세계의 통증 관리 치료제 시장 : 통증 유형별, 약제 클래스별, 투여 경로별, 최종 사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 점유율, 예측(2025-2032년)

Pain Management Therapeutics Market, By Type of Pain, By Drug Class, By Administration Route, By End-user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 05월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 398 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

통증 관리 치료제 시장 규모는 2024년 849억 7,800만 달러로 평가되었고, 2025-2032년 연평균 복합 성장률(CAGR) 3.78%로 확대될 전망입니다.

이 시장을 견인하는 요인으로는 만성 질환의 유병률 상승, 인구 고령화, 통증 관리 선택지에 대한 의식의 고조 등을 들 수 있습니다. 또, 약제의 제제 및 전달 방법의 혁신도 치료의 가능성을 넓히고 있습니다. 더욱이, 비중독성으로 보다 안전한 대체 진통제에 대한 수요의 고조가 시장 동향을 형성하고 있습니다. 이 분야는 암, 관절염, 신경 장애성 질환, 수술 후 회복과 관련된 통증을 대상으로 하고 있습니다. 전체적으로, 전세계에서 경험되는 가장 일반적이고 과제가 되고 있는 증상의 하나에 대처하는 것으로, 의료에 있어서 중요한 역할을 하고 있습니다.

통증 관리 치료제 시장 역학

비오피오이드계 진통제에 대한 수요가 증가함에 따라 보다 안전한 대체 요법이 촉진됩니다.

비오피오이드계 진통제에 대한 수요 증가는 통증 관리 치료제 시장의 중요한 촉진요인입니다. 오피오이드의 중독, 남용, 부작용에 대한 우려가 환자와 의료 제공자 모두에게 보다 안전한 대체 요법을 요구하도록 촉구하고 있습니다. 비스테로이드성 항염증제(NSAID), 항경련제, 항우울제, 국소 치료제 등의 비오피오이드계 치료제는 더 낮은 위험 프로필에서 효과적인 통증 완화를 제공합니다.

이 변화는 세계 의식 향상 캠페인 및 오피오이드 처방에 대한 규제 강화에 의해 지원됩니다. 또한, 연구의 진보로 통증 메커니즘을 보다 정확하게 표적으로 하는 혁신적인 비오피오이드 약물이 생성되고 있습니다. 그 결과 시장은 이러한 안전한 옵션을 포함한 포트폴리오를 확대하고 있습니다. 이 동향은 오피오이드의 장기 사용이 종종 문제가 되는 만성 통증 질환의 관리에 특히 중요합니다. 전반적으로 비오피오이드 치료에 대한 수요는 치료 접근법을 재구성하고 시장 성장을 가속화하고 있습니다.

통증 관리 치료제 시장 : 주요 고려 사항

당사의 리서치 애널리스트의 분석에 따르면 세계 시장은 예측 기간(2025-2032년) 약 3.78%의 연평균 복합 성장률(CAGR)로 연간 성장할 것으로 추정됩니다.

통증 유형별 세분화에서는 만성 통증이 2024년에 최대 시장 점유율을 나타낸 것으로 평가되었습니다.

약제 클래스별로 오피오이드는 2024년 주요 약물 클래스였습니다.

투여 경로별로 경구제는 2024년 시장을 선도했습니다.

최종 사용자 세분화에서는 2024년 병원이 주요 시장이 되었습니다.

지역별로는 북미가 2024년 매출액 1위를 차지했습니다.

통증 관리 치료제 시장 : 세분화 분석

세계의 통증 관리 치료제 시장은 통증 유형, 약제 클래스별, 유통, 최종 사용자 및 지역에 따라 세분화됩니다.

통증 유형별로는 급성 통증, 만성 통증, 암성 통증, 신경장애성 통증, 수술 후 통증의 5가지로 분류됩니다. 만성 통증은 널리 만연하고 장기간 지속되는 성질이 있기 때문에 통증 관리 치료제 시장에서 지배적인 부문입니다. 부상이나 수술과 관련된 일시적인 급성 통증과는 달리 만성 통증은 수개월에서 수년에 걸쳐 지속되며, 많은 경우 관절염, 신경장애, 섬유근통증 등의 질환에 기인합니다. 만성 통증은 환자의 QOL이나 일상생활에 큰 영향을 미치기 때문에 그 관리는 매우 어렵습니다. 이 때문에 효과적이고 지속 가능한 통증 완화 요법에 대한 수요가 높아지고 있습니다. 세계의 고령화 및 만성 질환 증가는 만성 통증을 타깃으로 한 혁신적인 치료법의 필요성을 더욱 높이고 있습니다.

시장은 약제 클래스별로 다섯 가지 범주로 분류됩니다. 오피오이드, 비 오피오이드 진통제, 보조 진통제, 국소 진통제 및 기타 유형입니다. 오피오이드는 중등도에서 심한 통증을 완화하는 강한 유효성으로 인해 통증 관리 치료제 시장에서 여전히 지배적인 약제 클래스별입니다. 오피오이드는 뇌나 척수의 오피오이드 수용체에 결합함으로써 작용해 통증 지각을 현저히 떨어뜨립니다. 그 높은 유효성에도 불구하고 중독이나 부작용의 우려로 규제가 강화되어 신중한 사용이 요구되고 있습니다. 그러나 오피오이드는 특히 암성 통증이나 수술 후 통증 관리에 널리 처방되고 있습니다. 보다 안전한 오피오이드 제제의 개발이 진행되고 있는 것은 통증 완화와 위험 최소화의 균형을 맞추기 위함이며, 통증 치료제에서 오피오이드의 중요한 역할은 유지되고 있습니다.

통증 관리 치료제 시장 : 지역별 분석

북미는 의료 인프라가 정비되어 있어 만성 통증 질환의 유병률이 높기 때문에 통증 관리 치료제 시장에서 우세한 지위를 차지하고 있습니다. 미국은 고령화에 따른 관절염, 암, 신경장애성 통증의 증가로 시장을 선도하고 있습니다. 게다가 통증 관리의 선택지에 대한 의식의 고조와 선진적인 치료법 보급이 시장 성장에 기여하고 있습니다. 이 지역의 규제 당국은 보다 안전한 통증 관리를 추진하고 있으며, 이것이 비오피오이드 대체약으로의 시프트를 가속시키고 있습니다.

미국은 북미의 통증 관리 치료 시장에서 가장 큰 공헌국이며, 만성 통증 질환의 높은 유병률과 고령화가 그 요인이 되고 있습니다. 오피오이드 중독에 대한 의식의 고조가 보다 안전한 비오피오이드 진통 옵션에 대한 수요를 뒷받침하고 있습니다. 견고한 의료 인프라, 선진적인 조사, 통증 관리를 지원하는 정부의 대처가 시장의 성장을 더욱 뒷받침하고 있습니다. 주요 제약 기업의 존재도 통증 치료제의 지속적인 기술 혁신을 촉진하고 있습니다.

통증 관리 치료제 시장 : 경쟁 구도

통증 관리 치료제 시장 경쟁 구도는 매우 역동적이며 주요 제약 기업과 생명 공학 기업 간의 격렬한 적대 관계가 특징입니다. 주요 기업들은 시장에서의 지위를 강화하기 위해 제품의 혁신, 전략적 제휴, 인수에 주력하고 있습니다. 각사는, 규제 요건이나 환자 기호의 변화에 대응하기 위해, 보다 안전하고 효과적인 통증 완화약, 특히 비오피오이드 요법을 개발하기 위한 연구 개발에 고액의 투자를 실시하고 있습니다.

시장은 또한 제제, 전달 기술 및 가격 전략에 기반한 경쟁에도 참여하고 있습니다. 참신한 치료 솔루션을 가진 신흥 기업들이 기존 기업들에 과제를 내 더 많은 기술 혁신을 촉구하고 있습니다. 게다가 기업은 제휴나 라이선싱 계약을 통해서 지리적 존재감을 확대하고 있습니다. 오피오이드 위기의 진행에 의해, 각사는 대체 통증 관리 요법의 개발을 가속시키고 있어 시장 경쟁은 격화되고 있습니다. 전반적으로 이러한 경쟁 환경은 전 세계 환자와 의료 제공자에게 이익을 가져다주는 끊임없는 진보를 촉진하고 있습니다.

서문
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 스웨덴
- 러시아
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 중국
- 인도
- 일본
- 한국
- 호주
- 인도네시아
- 태국
- 필리핀
- 기타
라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카(MEA)
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 : 통증 관리 치료제 업계

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 프로파일
- Johnson &Johnson
- Pfizer Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Novartis AG
- Grunenthal GmbH
- Mylan NV
- Mallinckrodt Pharmaceuticals
- Sanofi SA
- Allergan(AbbVie)
- AstraZeneca plc
- Endo International plc
- Bristol-Myers Squibb
- Bayer AG
- AcelRx Pharmaceuticals

제13장 AnalystView의 전방위 분석

AJY 25.07.02

REPORT HIGHLIGHT

Pain Management Therapeutics Market size was valued at US$ 84,978 Million in 2024, expanding at a CAGR of 3.78% from 2025 to 2032.

The Pain Management Therapeutics Market focuses on treatments and medications designed to relieve or reduce pain caused by various medical conditions. This market includes a wide range of products such as opioids, non-opioid analgesics, anti-inflammatory drugs, topical agents, and advanced therapies like nerve blocks and neuromodulation. The primary goal is to improve patient quality of life by managing acute and chronic pain effectively.

Factors driving this market include the rising prevalence of chronic diseases, an aging population, and increasing awareness about pain management options. Innovations in drug formulations and delivery methods are also expanding therapeutic possibilities. Additionally, the growing demand for non-addictive and safer pain relief alternatives is shaping market trends. The sector covers pain related to cancer, arthritis, neuropathic conditions, and postoperative recovery. Overall, it plays a critical role in healthcare by addressing one of the most common and challenging symptoms experienced worldwide.

Pain Management Therapeutics Market- Market Dynamics

Rising demand for non-opioid pain relief fuels safer therapeutic alternatives.

The rising demand for non-opioid pain relief is a significant driver in the Pain Management Therapeutics Market. Concerns over opioid addiction, abuse, and side effects have pushed both patients and healthcare providers to seek safer alternatives. Non-opioid therapies, including NSAIDs, anticonvulsants, antidepressants, and topical treatments, offer effective pain relief with lower risk profiles.

This shift is supported by growing awareness campaigns and stricter regulations on opioid prescriptions worldwide. Additionally, advancements in research are producing innovative non-opioid drugs that target pain mechanisms more precisely. As a result, the market is expanding its portfolio to include these safer options. This trend is especially important in managing chronic pain conditions, where long-term opioid use is often problematic. Overall, the demand for non-opioid therapies is reshaping treatment approaches and accelerating market growth.

Pain Management Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.78% over the forecast period (2025-2032)

Based on Type of Pain segmentation, Chronic Pain was predicted to show maximum market share in the year 2024

Based on Drug Class segmentation, Opioids was the leading Drug Class in 2024

Based on Administration Route segmentation, Oral was the leading distribution in 2024

Based on end-user segmentation, Hospitals was the leading distribution in 2024

On the basis of region, North America was the leading revenue generator in 2024

Pain Management Therapeutics Market- Segmentation Analysis:

The Global Pain Management Therapeutics Market is segmented on the basis of Type of Pain, Drug Class, Distribution, End-user, and Region.

The market is divided into five categories based on Type of Pain: Acute Pain, Chronic Pain, Cancer Pain, Neuropathic Pain, Postoperative Pain. Chronic pain is the dominant segment in the Pain Management Therapeutics Market due to its widespread prevalence and long-lasting nature. Unlike acute pain, which is temporary and linked to injury or surgery, chronic pain persists for months or years, often resulting from conditions like arthritis, neuropathy, or fibromyalgia. Managing chronic pain is challenging because it significantly affects patients' quality of life and daily functioning. This has led to a growing demand for effective and sustainable pain relief therapies. The rising number of aging populations and chronic disease cases worldwide further drive the need for innovative treatments targeting chronic pain.

The market is divided into five categories based on Drug Class: Opioids, Non-Opioid Analgesics, Adjuvant Analgesics, Topical Analgesics, Others. Opioids remain the dominant drug class in the Pain Management Therapeutics Market due to their strong effectiveness in relieving moderate to severe pain. They work by binding to opioid receptors in the brain and spinal cord, significantly reducing pain perception. Despite their high efficacy, concerns over addiction and side effects have led to increased regulation and cautious use. However, opioids continue to be widely prescribed, especially for cancer pain and postoperative pain management. The ongoing development of safer opioid formulations aims to balance pain relief with minimizing risks, maintaining their key role in pain therapeutics.

Pain Management Therapeutics Market- Geographical Insights

The North American region holds a dominant position in the Pain Management Therapeutics Market due to its well-established healthcare infrastructure and high prevalence of chronic pain conditions. The United States leads the market, driven by increasing cases of arthritis, cancer, and neuropathic pain among its aging population. Additionally, growing awareness about pain management options and widespread adoption of advanced therapies contribute to market growth. Regulatory agencies in the region are promoting safer pain management practices, which has accelerated the shift toward non-opioid alternatives.

The United States is the largest contributor to the Pain Management Therapeutics Market within North America, driven by a high prevalence of chronic pain conditions and an aging population. Increased awareness about opioid addiction has boosted demand for safer, non-opioid pain relief options. Robust healthcare infrastructure, advanced research, and government initiatives supporting pain management further strengthen market growth. The presence of leading pharmaceutical companies also fosters continuous innovation in pain therapeutics.

Pain Management Therapeutics Market- Competitive Landscape:

The competitive landscape of the Pain Management Therapeutics Market is highly dynamic and characterized by intense rivalry among leading pharmaceutical and biotech companies. Key players focus on product innovation, strategic partnerships, and acquisitions to strengthen their market positions. Companies are investing heavily in research and development to create safer and more effective pain relief options, particularly non-opioid therapies, to meet changing regulatory requirements and patient preferences.

The market also witnesses competition based on drug formulations, delivery technologies, and pricing strategies. Emerging players with novel therapeutic solutions are challenging established firms, driving further innovation. Additionally, companies are expanding their geographic presence through collaborations and licensing agreements. The ongoing opioid crisis has pushed companies to accelerate development of alternative pain management therapies, increasing market competition. Overall, this competitive environment fosters continuous advancements that benefit patients and healthcare providers worldwide.

Recent Developments:

In January 2025, Vertex Pharmaceuticals received FDA approval for Journavx (suzetrigine), a novel non-opioid painkiller for moderate-to-severe acute pain. This marks the first approval of a new class of pain medication in over two decades. Journavx targets sodium channels specific to pain neurons, offering effective pain relief without the addictive potential of opioids. The approval signifies a significant advancement in non-opioid pain management options.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as following:

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Johnson & Johnson
Pfizer Inc.
AbbVie Inc.
Teva Pharmaceutical Industries Ltd.
Eli Lilly and Company
Novartis AG
Grunenthal GmbH
Mylan N.V.
Mallinckrodt Pharmaceuticals
Sanofi S.A.
Allergan (AbbVie)
AstraZeneca plc
Endo International plc
Bristol-Myers Squibb
Bayer AG
AcelRx Pharmaceuticals

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY TYPE OF PAIN- MARKET ANALYSIS, 2019 - 2032

Acute Pain
Chronic Pain
Cancer Pain
Neuropathic Pain
Postoperative Pain

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Opioids
Non-Opioid Analgesics
Adjuvant Analgesics
Topical Analgesics
Others

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY ADMINISTRATION ROUTE- MARKET ANALYSIS, 2019 - 2032

Oral
Injectable
Transdermal
Topical

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Ambulatory Surgical Centers
Home Care Settings
Others

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Pain Management Therapeutics Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Pain Management Therapeutics Market Snippet by Type of Pain
- 2.1.2. Pain Management Therapeutics Market Snippet by Drug Class
- 2.1.3. Pain Management Therapeutics Market Snippet by Administration Route
- 2.1.4. Pain Management Therapeutics Market Snippet by End-user
- 2.1.5. Pain Management Therapeutics Market Snippet by Country
- 2.1.6. Pain Management Therapeutics Market Snippet by Region
2.2. Competitive Insights

3. Pain Management Therapeutics Key Market Trends

3.1. Pain Management Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Pain Management Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Pain Management Therapeutics Market Opportunities
3.4. Pain Management Therapeutics Market Future Trends

4. Pain Management Therapeutics Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Pain Management Therapeutics Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Pain Management Therapeutics Market Landscape

6.1. Pain Management Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Pain Management Therapeutics Market - By Type of Pain

7.1. Overview
- 7.1.1. Segment Share Analysis, By Type of Pain, 2024 & 2032 (%)
- 7.1.2. Acute Pain
- 7.1.3. Chronic Pain
- 7.1.4. Cancer Pain
- 7.1.5. Neuropathic Pain
- 7.1.6. Postoperative Pain

8. Pain Management Therapeutics Market - By Drug Class

8.1. Overview
- 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
- 8.1.2. Opioids
- 8.1.3. Non-Opioid Analgesics
- 8.1.4. Adjuvant Analgesics
- 8.1.5. Topical Analgesics
- 8.1.6. Others

9. Pain Management Therapeutics Market - By Administration Route

9.1. Overview
- 9.1.1. Segment Share Analysis, By Administration Route, 2024 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Injectable
- 9.1.4. Transdermal
- 9.1.5. Topical

10. Pain Management Therapeutics Market - By End-user

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Ambulatory Surgical Centers
- 10.1.4. Home Care Settings
- 10.1.5. Others

11. Pain Management Therapeutics Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Pain Management Therapeutics Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.2.8. The U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Pain Management Therapeutics Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Pain Management Therapeutics Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Pain Management Therapeutics Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Pain Management Therapeutics Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Pain Management Therapeutics Industry

12.1. Competitive Dashboard
- 12.1.1. Competitive Benchmarking
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. Johnson & Johnson
- 12.2.2. Pfizer Inc.
- 12.2.3. AbbVie Inc.
- 12.2.4. Teva Pharmaceutical Industries Ltd.
- 12.2.5. Eli Lilly and Company
- 12.2.6. Novartis AG
- 12.2.7. Grunenthal GmbH
- 12.2.8. Mylan N.V.
- 12.2.9. Mallinckrodt Pharmaceuticals
- 12.2.10. Sanofi S.A.
- 12.2.11. Allergan (AbbVie)
- 12.2.12. AstraZeneca plc
- 12.2.13. Endo International plc
- 12.2.14. Bristol-Myers Squibb
- 12.2.15. Bayer AG
- 12.2.16. AcelRx Pharmaceuticals

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us